2019
Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET
Holmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 2254-2264. PMID: 31744389, PMCID: PMC7585925, DOI: 10.1177/0271678x19886316.Peer-Reviewed Original ResearchConceptsEffects of ketamineKetamine infusionGlutamate transmissionMetabotropic glutamate receptor 5Ketamine-induced effectsKetamine-induced changesGlutamate receptor 5Promising treatment targetDrug challenge studiesTwo-tissue compartment modelMGluR5 radioligandBlood pressureMGluR5 availabilityBaseline scanOutcome measuresHealthy subjectsHeart ratePsychiatric disordersReceptor 5Modulatory effectsMGluR5Treatment targetsChallenge studiesArterial input functionChallenge paradigm
2015
Reference Region Modeling Approaches for Amphetamine Challenge Studies with [11C]FLB 457 and PET
Sandiego CM, Gallezot JD, Lim K, Ropchan J, Lin SF, Gao H, Morris ED, Cosgrove KP. Reference Region Modeling Approaches for Amphetamine Challenge Studies with [11C]FLB 457 and PET. Cerebrovascular And Brain Metabolism Reviews 2015, 35: 623-629. PMID: 25564239, PMCID: PMC4420880, DOI: 10.1038/jcbfm.2014.237.Peer-Reviewed Original ResearchConceptsPositron emission tomographyExtrastriatal regionsBrain regionsAmphetamine-induced dopamine releaseHealthy tobacco smokersExtrastriatal brain regionsSynaptic dopamine levelsAmphetamine-induced changesSimplified reference tissue modelReference tissue modelTobacco smokersDopaminergic dysfunctionAmphetamine administrationDopamine levelsDopamine releasePsychiatric disordersChallenge studiesDistribution volumeEmission tomographyD3 bindingReference region modelCerebellumReference regionBaselineSignificant changes
2010
Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo
Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, Malison RT, Carson RE, Ding YS. Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo. Biological Psychiatry 2010, 68: 854-860. PMID: 20691429, PMCID: PMC3742016, DOI: 10.1016/j.biopsych.2010.06.017.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderNET-rich regionsPositron emission tomographyNorepinephrine transporterDopamine transporterHyperactivity disorderRelevant dosesEmission tomographySingle-blind placeboMultilinear reference tissue modelEffective dose 50Attention deficit hyperactivity disorderDose-dependent mannerMechanism of actionDeficit hyperactivity disorderBrain norepinephrine transportersReference tissue modelMaintenance doseOral methylphenidateHealthy subjectsTherapeutic effectOccipital cortexCommon treatmentPsychiatric disordersMethylphenidate